StockData
Veracyte, Inc. logo

Veracyte, Inc. (VCYT) stock

VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$25.57+1.34 (+5.53%)

Close on Nov 18, 2026Market cap $2.06BP/E 18.3Yield –

Veracyte operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Veracyte's operating income for the twelve months ending Jun 30, 2026 was $105.77M, up 664.9% year over year. For fiscal 2025 it was $57.78M, up 257.9% from the year before. The highest annual figure on record is $57.78M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$57.78M+257.9%
FY2024Dec 31, 2024$16.14M–
FY2023Dec 31, 2023-$85.80M–
FY2022Dec 31, 2022-$41.08M–
FY2021Dec 31, 2021-$81.90M–
FY2020Dec 31, 2020-$35.39M–
FY2019Dec 31, 2019-$15.13M–
FY2018Dec 31, 2018-$22.23M–
FY2017Dec 31, 2017-$26.54M–
FY2016Dec 31, 2016-$28.80M–
FY2015Dec 31, 2015-$33.47M–
FY2014Dec 31, 2014-$29.01M–
FY2013Dec 31, 2013-$23.17M–
FY2012Dec 31, 2012-$18.93M–
FY2011Dec 31, 2011-$15.27M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$22.98M–
Q1 FY2026Mar 31, 2026$22.65M+679.8%
Q4 FY2025Dec 31, 2025$37.20M+790.9%
Q3 FY2025Sep 30, 2025$22.95M+90.9%
Q2 FY2025Jun 30, 2025-$5.27M-214.4%
Q1 FY2025Mar 31, 2025$2.90M–
Q4 FY2024Dec 31, 2024$4.18M–
Q3 FY2024Sep 30, 2024$12.02M–
Q2 FY2024Jun 30, 2024$4.61M–
Q1 FY2024Mar 31, 2024-$4.66M–
Q4 FY2023Dec 31, 2023-$35.51M–
Q3 FY2023Sep 30, 2023-$31.74M–
Q2 FY2023Jun 30, 2023-$8.05M–
Q1 FY2023Mar 31, 2023-$10.50M–
Q4 FY2022Dec 31, 2022-$5.42M–
Q3 FY2022Sep 30, 2022-$9.68M–
Q2 FY2022Jun 30, 2022-$10.73M–
Q1 FY2022Mar 31, 2022-$15.25M–
Q4 FY2021Dec 31, 2021-$12.33M–
Q3 FY2021Sep 30, 2021-$16.68M–
Q2 FY2021Jun 30, 2021-$7.47M–
Q1 FY2021Mar 31, 2021-$45.42M–
Q4 FY2020Dec 31, 2020-$8.07M–
Q3 FY2020Sep 30, 2020-$4.07M–
Q2 FY2020Jun 30, 2020-$11.05M–
Q1 FY2020Mar 31, 2020-$12.20M–
Q4 FY2019Dec 31, 2019-$8.20M–
Q3 FY2019Sep 30, 2019-$1.76M–
Q2 FY2019Jun 30, 2019-$3.10M–
Q1 FY2019Mar 31, 2019-$2.07M–
Q4 FY2018Dec 31, 2018-$3.06M–
Q3 FY2018Sep 30, 2018-$4.30M–
Q2 FY2018Jun 30, 2018-$5.92M–
Q1 FY2018Mar 31, 2018-$8.96M–
Q4 FY2017Dec 31, 2017-$6.04M–
Q3 FY2017Sep 30, 2017-$6.37M–
Q2 FY2017Jun 30, 2017-$6.61M–
Q1 FY2017Mar 31, 2017-$7.52M–
Q4 FY2016Dec 31, 2016-$3.67M–
Q3 FY2016Sep 30, 2016-$4.89M–

More Veracyte figures

See a number that looks wrong?